Iterum Therapeutics ITRMF
ITRMF
$0.00 +0.00 (+0.00%)
At close: Aug 19, 2026 · 4:00 PM EDT

Iterum Therapeutics plc (ITRMF) EBT (2017 - 2025)

Iterum Therapeutics (ITRMF) posted quarterly EBT of -$8.8 million for Q3 2025, down 48.49% year-over-year from -$17.2 million in Q3 2024, and down 37.16% quarter-over-quarter from -$6.4 million in Q2 2025.

Iterum Therapeutics plc (ITRMF) EBT (2017 - 2025) Analysis & Trends

Iterum Therapeutics' EBT history runs 9 years deep, the most recent figure standing at -$8.8 million for Q3 2025.

  • In Q3 2025, EBT fell 48.49% year-over-year to -$8.8 million; the TTM figure through Sep 2025 stood at -$1.8 million (down 119.14% YoY), while the FY2024 annual figure was $370000.0, down 78.77% from the prior year.
  • EBT for Q3 2025 stood at -$8.8 million, down from -$6.4 million in the prior quarter.
  • The five-year high for EBT was $27.3 million in Q4 2023, with the low at -$98.9 million in Q1 2021.
  • The 5-year median for EBT is -$5.0 million (2022), against an average of -$8.1 million.
  • The sharpest annual moves came in 2022 and 2023: EBT plunged 825.12% in 2022, then jumped 646.82% in 2023.
  • Iterum Therapeutics' EBT stood at -$4.0 million in 2021, then slipped by 25.45% to -$5.0 million in 2022, then surged by 646.82% to $27.3 million in 2023, then plunged by 32.75% to $18.3 million in 2024, then slumped by 148.22% to -$8.8 million in 2025.
  • Business Quant data shows ITRMF's EBT at -$8.8 million in Q3 2025, -$6.4 million in Q2 2025, and -$4.8 million in Q1 2025.

Peer Comparison

Historic Data

Download Data
DateValue
Sep 30, 2025 -8.85 Mn
Jun 30, 2025 -6.45 Mn
Mar 31, 2025 -4.83 Mn
Dec 31, 2024 18.35 Mn
Sep 30, 2024 -5.96 Mn
Jun 30, 2024 -4.97 Mn
Mar 31, 2024 -7.05 Mn
Dec 31, 2023 27.28 Mn
Sep 30, 2023 -3.72 Mn
Jun 30, 2023 -12.06 Mn
Mar 31, 2023 -9.77 Mn
Dec 31, 2022 -4.99 Mn
Sep 30, 2022 -29.68 Mn
Jun 30, 2022 -6.39 Mn
Mar 31, 2022 -3.07 Mn
Dec 31, 2021 -3.98 Mn
Sep 30, 2021 4.09 Mn
Jun 30, 2021 7.92 Mn
Mar 31, 2021 -98.86 Mn
Dec 31, 2020 40.80 Mn